OSU-16077: Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov) - Sep 25, 2026 - P2 | N=18 | Active, not recruiting | Sponsor: Ohio State University Comprehensive Cancer Center | Trial completion date: Aug 2026 ➔ Feb 2027 | Trial primary completion date: Aug 2026 ➔ Feb 2027
Trial completion date • Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology
|